Results research

Concall Intelligence

Follow the Sept 2026 quarter results season by comparing what companies reported with what management said next. Search transcript evidence, measurable guidance, changing outlook, operating risks, and prior commitments without treating commentary as a trading recommendation.

Open reported results

Matching calls

After selected filters

Loaded now

Page 1 of 1

Summaries ready

Source-linked evidence in this page

Tracked companies

Watchlist or portfolio matches

Management evidence

Generated 21 Oct, 10:55 pm IST · click a summary to inspect source-linked evidence for this results quarter.

Clear filters

Company	Call and sources	Reported result	Management outlook	Evidence-led conclusion
INDIANB Indian Bank Financial Services · Mid	Sept 2026 21 Oct 2026 Transcript	Good 60/100	Outlook pending No comparable prior call Guidance pending	The transcript is available but has not produced sufficient structured evidence. Summary pending
CCL CCL Products (India) Limited FMCG · Large	Sept 2026 21 Oct 2026 Transcript	Average 47/100	Optimistic outlook No comparable prior call Guidance maintained	CCL delivered strong Q2 results with double‑digit volume growth and profit expansion, and management reaffirmed its FY27 guidance of ~15% volume and EBITDA growth, while noting coffee price volatility and capacity considerations. Evidence summary ready
DBCORP D.B.Corp Limited Media · Small	Sept 2026 21 Oct 2026 Transcript	Bad 0/100	Outlook pending No comparable prior call Guidance pending	The transcript is available but has not produced sufficient structured evidence. Summary pending
UJJIVANSFB Ujjivan Small Finance Bank Limited Financial Services · Micro	Sept 2026 19 Oct 2026 Transcript PPT	Excellent 85/100	Optimistic outlook No comparable prior call Guidance maintained	Ujjivan Small Finance Bank announced the early retirement of its MD & CEO due to health reasons and appointed Ms. Carol Furtado as Interim MD & CEO. Management reassured stakeholders of continuity in strategy, strong governance, and commitment to FY27 guidance, emphasizing that growth plans and capital adequacy remain unaffected by the leadership transition or potential delays in capital raising. The search for a permanent MD & CEO has been expedited. Evidence summary ready

Method: Deterministic quarterly-result score from reported growth, margin direction and operating leverage. Derived only from extracted, source-linked management evidence. Pending is shown when evidence is insufficient. Measurable claims are separated from general commentary and retain outcome status when later evidence exists. Management outlook and colours describe extracted commentary evidence; they are not buy or sell labels.